William Blair Remains a Buy on Biohaven Pharmaceutical Holding Co (BHVN)


In a report issued on August 6, Tim Lugo from William Blair maintained a Buy rating on Biohaven Pharmaceutical Holding Co (BHVN). The company’s shares closed last Friday at $67.65.

According to TipRanks.com, Lugo is a 5-star analyst with an average return of 16.2% and a 49.5% success rate. Lugo covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Adamas Pharmaceuticals, and Eagle Pharmaceuticals.

Currently, the analyst consensus on Biohaven Pharmaceutical Holding Co is a Strong Buy with an average price target of $86.38, implying a 35.6% upside from current levels. In a report issued on July 29, Piper Sandler also maintained a Buy rating on the stock with a $100.00 price target.

See today’s analyst top recommended stocks >>

Based on Biohaven Pharmaceutical Holding Co’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.15 million and GAAP net loss of $173 million. In comparison, last year the company had a GAAP net loss of $62.3 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts